Media Advisory: Human Gene-Editing Study - Feb. 11 Public Meeting
New gene-editing technologies such as CRISPR-Cas9 hold great promise for treating disease, but they also raise concerns, particularly because of their potential to be used to make genetic changes that could be passed on to future generations, thereby modifying the human germline.
On Feb. 11, a National Academy of Sciences and National Academy of Medicine committee that is conducting a comprehensive consensus study on the scientific, medical, and ethical considerations of human gene editing – including germline editing -- will hold an information-gathering meeting. Invited experts will discuss perspectives on human gene editing from representatives of the Sickle Cell Foundation of Tennessee, the Parent Project Muscular Dystrophy, the District of Columbia Association of the Deaf, and other potentially affected groups; how public attitudes and decision making intersect with science policy; and the potential for developing therapeutics using human gene-editing technologies.
Follow the conversation on Twitter using #GeneEditStudy.
The meeting will take place from 8 a.m. to 3:30 p.m. EST on Thursday, Feb. 11, in Room 100 of the Academies’ Keck Center, 500 Fifth St., N.W., Washington, D.C. Those who cannot attend in person may watch via webcast at www.nationalacademies.org. A full agenda, registration, and more information about the study can be found at nationalacademies.org/gene-editing/consensus-study. Seating is limited; members of the media who wish to attend must register in advance with the Office of News and Public Information; tel. 202-334-2138 or e-mail email@example.com.
The consensus study is a component of the NAS and NAM initiative on human gene editing. The study committee's report is expected in late 2016.